Compare JELD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JELD | CGTX |
|---|---|---|
| Founded | 1960 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.5M | 114.4M |
| IPO Year | 2016 | 2021 |
| Metric | JELD | CGTX |
|---|---|---|
| Price | $1.63 | $1.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $3.43 | $3.33 |
| AVG Volume (30 Days) | ★ 2.2M | 997.7K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $0.22 |
| 52 Week High | $6.98 | $3.83 |
| Indicator | JELD | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 58.69 |
| Support Level | $0.93 | $1.01 |
| Resistance Level | $2.06 | $1.36 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 90.72 | 62.50 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).